BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.30 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 2.95M

Average 4.85M

BCRX Income Before Tax

Profit after all operating and non-operating items but before income tax.

BioCryst Pharmaceuticals, Inc.NASDAQ: BCRX

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax growth accelerates

Q2 FY2026 income before tax of $79.47M rose 1125.3% year over year, ahead of the -1084.0% change in trailing-twelve-month income before tax.

Context

  • Income before tax amounted to 30.6% of revenue in FY2025, up 11.3 pp from a year earlier.
  • Income before tax increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1125.3% holds above the trailing-twelve-month pace of -1084.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$79.47M+111.0% QoQ
Last fiscal yearDec 2025
$267.39M+407.5% YoY
LTMJun 2026
-$381.19M-1084.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1125.3%——
1 year+407.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
267.39M USD
Year-over-year change
+407.5%

Income Before Tax vs competitors

How BCRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1084.0% is the lowest of 4, against a peer median of -8.9%.
  • Income before tax amounts to 40.5% of revenue for BCRX, versus a peer median of 675.4%.
BCRX Competitors
Income Before Tax for BCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$175.83M USD-26.9%——
PHVSPharvaris N.V.LTM Sep 2026-€179.08M EUR-8.9%——
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026-$381.19M USD-1084.0%—40.5%
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.35M USD+23.6%—675.4%
Peer median (excluding BCRX) —-8.9%—675.4%

Competitors are the stored peer set for BCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue157.17M270.83M331.41M450.71M874.84M
Cost of Revenue7.26M6.59M4.66M12.49M19.08M
Gross Profit149.91M264.23M326.75M438.23M855.76M
Gross Margin95.4%97.6%98.6%97.2%97.8%
Research & Development208.81M253.3M216.57M174.64M166.13M
Selling, General & Admin118.82M159.37M213.89M266.13M348.65M
Operating Expenses327.63M412.67M430.46M440.77M514.77M
Depreciation & Amortization777K1.44M1.66M1.25M1.39M
EBITDA(121.74M)(143.85M)(116.34M)12.81M347.65M
EBITDA Margin-77.5%-53.1%-35.1%2.8%39.7%
Operating Income(177.72M)(148.44M)(103.71M)(2.54M)340.99M
Operating Margin-113.1%-54.8%-31.3%-0.6%39.0%
Interest Income62K5.13M15.78M14.75M10.67M
Interest Expense59.29M99.09M108.24M98.52M78.87M
Other Income / Expenses(4.09M)(95.95M)(122.52M)(84.41M)(73.6M)
Income Before Tax(181.81M)(244.38M)(226.23M)(86.95M)267.39M
Pre-Tax Margin-115.7%-90.2%-68.3%-19.3%30.6%
Income Tax Expense2.25M2.73M310K1.93M3.53M
Net Income(184.06M)(247.12M)(226.54M)(88.88M)263.86M
Net Margin-117.1%-91.2%-68.4%-19.7%30.2%
EPS (Basic)(1.03)(1.33)(1.18)(0.43)1.26
EPS (Diluted)(1.03)(1.33)(1.18)(0.43)1.21
Weighted Avg Shares179.12M185.91M192.2M206.7M209.89M
Weighted Avg Shares (Diluted)179.12M185.91M192.2M206.7M218.58M

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Intrinsic Alpha fair value

Locked

Current Price

$7.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.